Antibody Drug Conjugates Market 2019 Global Industry Size, Share, Business GrowPosted by Rashi Pande on January 7th, 2020 Global antibody drug conjugates market is expected to grow at a growing CAGR of 23.46 %in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Few of the major competitors currently working in the global antibody drug conjugates market are Alteogen, F. Hoffmann-La Roche Ltd, Astellas Pharma Inc, Seattle Genetics, Inc, ImmunoGen Inc, Pfizer Inc, AbbVie Inc, Takeda Pharmaceutical Company Limited, LegoChem Biosciences, Inc, Daiichi Sankyo Company, AstraZeneca, Eli Lilly and Company, CELGENE CORPORATION, Sutro Biopharma, Inc, Sanofi, INNATE PHARMA S.A, Progenics Pharmaceuticals, Inc, Sorrento Therapeutics, Inc, Synthon International Holding B.V. , Novartis AG and others Get Exclusive Sample Report + All Related Graphs & Charts HereMarket Definition: Global Antibody Drug Conjugates Market Antibody-Drug Conjugates are the chemical linker which connects cytotoxic agents to the antibody. This enables the ADC to target and bind to cell-surface proteins called antigens that can be found on cancer cells and release its cell-killing drugs only after it has been internalized by the cancer cell. Market Drivers
Market Restraints
Key Developments in the Market:
Competitive Analysis: Global antibody drug conjugates market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global antibody drug conjugates market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa. Like it? Share it!More by this author |